Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
PathwayREACTOME_ADAPTIVE_IMMUNE_SYSTEM

CUL2 RNF213 LILRA4

5.91e-0382873M1058
PathwayREACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION

CUL2 RNF213

8.78e-0329972MM15711
PathwayREACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION

CUL2 RNF213

9.29e-0330872M1070
PathwayREACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION

CUL2 RNF213

1.14e-0234372MM15712
PathwayREACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION

CUL2 RNF213

1.40e-0238172M1066
Pubmed

BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62.

ZNF318 RNF213 SEC16A

1.04e-0515610332850835
Pubmed

SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.

CUL2 HNRNPUL2 BDH1 SEC16A

2.39e-0565510435819319
Pubmed

Quantitative Proteomics Reveals Dynamic Interactions of the Minichromosome Maintenance Complex (MCM) in the Cellular Response to Etoposide Induced DNA Damage.

ZNF318 HNRNPUL2 RNF213 SEC16A

6.44e-0584410425963833
Pubmed

Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex.

RNF213 BDH1 SEC16A

7.58e-0530410332235678
Pubmed

Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.

ZNF318 HNRNPUL2 SEC16A

2.26e-0444010334244565
Pubmed

Myosin-X recruits lamellipodin to filopodia tips.

CUL2 SEC16A

2.88e-048910236861887
InteractionAR interactions

CUL2 ZNF318 HNRNPUL2 RNF213 SEC16A

1.41e-0599285int:AR
InteractionPDCD6 interactions

CUL2 HNRNPUL2 SEC16A

5.51e-0520483int:PDCD6
InteractionTRIM66 interactions

ZNF318 RNF213 SEC16A

5.59e-0520583int:TRIM66
InteractionRNF113A interactions

CUL2 HNRNPUL2 BDH1 SEC16A

8.64e-0569284int:RNF113A
InteractionPRPF39 interactions

CUL2 ZNF318

1.74e-045182int:PRPF39
InteractionHNRNPK interactions

CUL2 HNRNPUL2 RNF213 SEC16A

1.95e-0485384int:HNRNPK
InteractionCUL4A interactions

CUL2 RNF213 BDH1 SEC16A

1.95e-0485484int:CUL4A
InteractionGLDC interactions

CUL2 HNRNPUL2 SEC16A

2.11e-0432183int:GLDC
InteractionEEF1D interactions

CUL2 HNRNPUL2 SEC16A

2.35e-0433383int:EEF1D
InteractionBAG5 interactions

ZNF318 RNF213 SEC16A

2.52e-0434183int:BAG5
InteractionWDR77 interactions

CUL2 HNRNPUL2 SEC16A

2.99e-0436183int:WDR77
CytobandEnsembl 112 genes in cytogenetic band chr19q13

FBXO46 LILRA4

2.64e-021192102chr19q13
CoexpressionGSE6269_STAPH_AUREUS_VS_STREP_PNEUMO_INF_PBMC_DN

ZNF318 HNRNPUL2 BDH1

3.63e-05179103M5664
CoexpressionGSE15750_DAY6_VS_DAY10_EFF_CD8_TCELL_DN

ZNF318 RNF213 SEC16A

5.05e-05200103M3579
CoexpressionGSE17721_CTRL_VS_LPS_4H_BMDC_UP

HNRNPUL2 BDH1 SEC16A

5.05e-05200103M3689
CoexpressionTOMLINS_PROSTATE_CANCER_UP

BDH1 SEC16A

1.01e-0440102M19148
CoexpressionBYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS

CUL2 MMP17 HNRNPUL2 SEC16A

1.46e-04786104M2388
ToppCellPND07-28-samps-Myeloid-Macrophage-macrophage-A|PND07-28-samps / Age Group, Lineage, Cell class and subclass

MMP17 RNF213

2.73e-04112102d21cfcb04a27cc9fb74e0c2afa8a8cdfb886ae21
ToppCellParenchymal-10x3prime_v2-Immune_Myeloid-Dendritic_cell-DC_plasmacytoid|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

LILRA4 BDH1

3.90e-041341020e3f37ef041b751ed45060b5ce39385a2731370b
ToppCellTCGA-Thymus-Primary_Tumor-Thymoma-Type_B2|TCGA-Thymus / Sample_Type by Project: Shred V9

TRBV10-3 LILRA4

5.01e-04152102752fdd3d55f5ad5a21562934a218e1fd50d152b1
ToppCellBronchial_Biopsy-Immune-Neutrophils|Immune / Tissue, Lineage and Cell class of Lung Cells from 10X

CUL2 MMP17

5.69e-04162102985adca17b0c99563feef7910f3da5df31e636b6
ToppCelldroplet-Lung-30m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l5|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

MMP17 BDH1

6.19e-041691021de3ae36d3b60e961bfd9f7bdc37867b82a0417f
ToppCell367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_6|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)

CUL2 FBXO46

6.41e-04172102da959c1abadafd79b7a0088a25eb8ef8efa3a0c2
ToppCellfacs-Trachea-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l39|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

MMP17 BDH1

6.78e-04177102928118b0ed120ec01c7d753ce523ab609ac24e5f
ToppCellPBMC-Convalescent-Lymphocyte-B-B_cell-B_naive-B_naive-9|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

ZNF318 MMP17

6.78e-04177102ae55773c531099a9e94f44f01ba48b5e71dddc53
ToppCellTCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-7|TCGA-Prostate / Sample_Type by Project: Shred V9

FBXO46 BDH1

7.17e-04182102af16334fec2c757b03c84cf252d00e92fa81e4cd
ToppCellTCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma|TCGA-Prostate / Sample_Type by Project: Shred V9

BDH1 SEC16A

7.41e-041851029d53e0a92e4f99370be2e4be1dd737630796b1ca
ToppCell10x5'-GI_large-bowel-Lymphocytic_B-Naive_B_cells|GI_large-bowel / Manually curated celltypes from each tissue

ZNF318 MMP17

7.41e-041851021c99373c123b5e0de40b47d9d885974a747b9839
ToppCellTCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma|TCGA-Prostate / Sample_Type by Project: Shred V9

BDH1 SEC16A

7.56e-04187102fa0452f3382c22c0391b241d06504fda3c6a19f0
ToppCellTCGA-Prostate-Primary_Tumor|TCGA-Prostate / Sample_Type by Project: Shred V9

BDH1 SEC16A

7.56e-041871023e6a95c912dad5d61e10497ffaafd2b9027cd13a
ToppCellbackground-B_cells|background / Sample and Cell Type and Tumor Cluster (all cells)

ZNF318 LILRA4

7.65e-041881029acb7a95e3095f15918a5d094107d1d565a42842
ToppCellControl-B_intermediate-6|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)

RNF213 LILRA4

7.73e-0418910211cb9a16f1de8f60af2073ed7ea6d4f41c02f299
ToppCell367C-Lymphocytic-NK_cells-NK_cell_B1|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

CUL2 ZNF318

7.81e-041901022434b8ad2976eab7d9147012c28454ab29670709
ToppCell367C-Lymphocytic-NK_cells-NK_cell_B1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

CUL2 ZNF318

7.89e-0419110239ef8e1d7cc3ebb11717e8a55501515e3b72b177
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-D|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

CUL2 LILRA4

8.14e-04194102b829a63b51b92507a53ffd0393bd9458b2b9440f
ToppCell10x5'-lymph-node_spleen-Lymphocytic_B-Naive_B_cells|lymph-node_spleen / Manually curated celltypes from each tissue

ZNF318 MMP17

8.14e-0419410220967afbadb3cf80ba9f4d7ebda4e64389252e70
ToppCelldistal-1-Hematologic-Nonclassical_Monocyte|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

MMP17 LILRA4

8.22e-04195102e1a8171d1af53c2bbda758170c5053d3a3bb6ddd
ToppCell10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_cytotoxic-C|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

RNF213 BDH1

8.22e-0419510283c125223e7ca0f08a31414b3a16347912564765
ToppCellproximal-Hematologic-IGSF21+_Dendritic-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

ZNF318 HNRNPUL2

8.22e-04195102ae9d61011e95f7840cbb154738c79745fd29943e
ToppCellproximal-Hematologic-IGSF21+_Dendritic|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

ZNF318 HNRNPUL2

8.22e-04195102c48ff83c48342875f06c6c9e7d5bc6084a992848
ToppCellproximal-3-Hematologic-IGSF21+_Dendritic|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

ZNF318 HNRNPUL2

8.22e-041951028592d0332bc82a91e173680cfd1afc5ee189b289
ToppCell3'-Pediatric_IBD-SmallIntestine-Hematopoietic-B_cells-GC_B_cell|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ZNF318 LILRA4

8.30e-04196102d08f6143d148a897efacc854e4306455a9a9868c
ToppCelldistal-3-Hematologic-Nonclassical_Monocyte|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

MMP17 LILRA4

8.30e-04196102c1f3334bc09f5d0cfb9d998a3a64f0700426a357
ToppCellControl-Control-Lymphocyte-T/NK-NK_activated|Control / Disease, condition lineage and cell class

RNF213 SEC16A

8.47e-0419810276d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7
ToppCellmedial|World / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

RNF213 LILRA4

8.47e-04198102071658de0c43f302172692aa0b4b507dbad7be50
ToppCell10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8-CD8_cytotoxic-F_2|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

TRBV10-3 RNF213

8.56e-04199102fbbac5e9153e813db848d498eb715aa208568d8d
ToppCellmLN-B_cell-Follicular_B_cell|B_cell / Region, Cell class and subclass

ZNF318 MMP17

8.64e-042001028fbd27ffcfd0702ad3c340d32455e36a01617139
DrugAlexidine dihydrochloride [22573-93-9]; Down 200; 6.8uM; PC3; HT_HG-U133A

ZNF318 HNRNPUL2 FBXO46

4.70e-05191937397_DN
DrugNorfloxacin [70458-96-7]; Down 200; 12.6uM; PC3; HT_HG-U133A

CUL2 ZNF318 HNRNPUL2

4.93e-05194937283_DN
Drug2-fluoroadenine arabinoside

ZNF318 LILRA4

1.67e-0315892CID000003367
Drugresveratrol; Down 200; 10uM; MCF7; HT_HG-U133A_EA

CUL2 HNRNPUL2

2.06e-0317692958_DN
DrugAnisomycin [22862-76-6]; Down 200; 15uM; HL60; HT_HG-U133A

ZNF318 BDH1

2.23e-03183921304_DN
DrugAmoxicillin [26787-78-0]; Down 200; 11uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.28e-03185922620_DN
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

CUL2 LILRA4

2.35e-03188926926_UP
Drugtroglitazone; Down 200; 10uM; PC3; HT_HG-U133A

FBXO46 BDH1

2.37e-03189921232_DN
DrugDisopyramide [3737-09-5]; Down 200; 11.8uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.40e-03190927439_DN
DrugPrimaquine diphosphate [63-45-6]; Down 200; 8.8uM; HL60; HT_HG-U133A

HNRNPUL2 FBXO46

2.40e-03190921343_DN
DrugSanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.42e-03191924168_DN
DrugDihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; PC3; HT_HG-U133A

ZNF318 BDH1

2.45e-03192922081_DN
Drug3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.45e-03192923382_DN
DrugTriamcinolone [124-94-7]; Down 200; 10.2uM; PC3; HT_HG-U133A

CUL2 BDH1

2.45e-03192922078_DN
DrugBisacodyl [603-50-9]; Down 200; 11uM; PC3; HT_HG-U133A

CUL2 HNRNPUL2

2.47e-03193924616_DN
DrugMuramic acid, N-acetyl [10597-89-4]; Down 200; 13.6uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.47e-03193924406_DN
Drugikarugamycin; Down 200; 2uM; MCF7; HT_HG-U133A_EA

CUL2 ZNF318

2.47e-0319392866_DN
Drug5114445; Down 200; 10uM; MCF7; HT_HG-U133A_EA

CUL2 HNRNPUL2

2.47e-0319392901_DN
Druggenistein; Down 200; 10uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.47e-03193925232_DN
DrugD-cycloserine [68-41-7]; Down 200; 39.2uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.47e-03193923562_DN
DrugBetahistine mesylate [54856-23-4]; Down 200; 17.2uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.47e-03193922833_DN
DrugDiphenidol hydrochloride [3254-89-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A

HNRNPUL2 FBXO46

2.47e-03193927447_DN
DrugDicumarol [66-76-2]; Down 200; 11.8uM; HL60; HT_HG-U133A

CUL2 HNRNPUL2

2.47e-03193922561_DN
DrugEthamivan [304-84-7]; Down 200; 18uM; PC3; HT_HG-U133A

CUL2 FBXO46

2.50e-03194927260_DN
Drugpioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A

MMP17 HNRNPUL2

2.50e-03194927523_UP
Drug5213008; Up 200; 18uM; MCF7; HT_HG-U133A_EA

ZNF318 HNRNPUL2

2.50e-0319492898_UP
DrugRonidazole [7681-76-7]; Down 200; 20uM; PC3; HT_HG-U133A

HNRNPUL2 FBXO46

2.50e-03194927131_DN
DrugPromazine hydrochloride [53-60-1]; Down 200; 12.4uM; PC3; HT_HG-U133A

HNRNPUL2 BDH1

2.50e-03194924308_DN
Drug0316684-0000 [391209-55-5]; Down 200; 10uM; PC3; HT_HG-U133A

HNRNPUL2 FBXO46

2.50e-03194927098_DN
DrugLynestrenol [52-76-6]; Up 200; 14uM; PC3; HG-U133A

ZNF318 BDH1

2.50e-03194921953_UP
DrugVerapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; HL60; HG-U133A

CUL2 HNRNPUL2

2.50e-03194922009_DN
Drugdiclofenac sodium; Up 200; 10uM; PC3; HG-U133A

MMP17 BDH1

2.53e-0319592445_UP
DrugPiperidolate hydrochloride [129-77-1]; Down 200; 11.2uM; HL60; HT_HG-U133A

CUL2 HNRNPUL2

2.53e-03195926129_DN
Drug15d-PGJ2; Up 200; 10uM; SKMEL5; HG-U133A

MMP17 HNRNPUL2

2.53e-0319592564_UP
DrugPyrithyldione [77-04-3]; Down 200; 24uM; HL60; HT_HG-U133A

CUL2 HNRNPUL2

2.53e-03195922740_DN
Drug5707885; Up 200; 50uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.53e-03195926433_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF318 MMP17

2.55e-03196923872_DN
DrugMefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; PC3; HT_HG-U133A

HNRNPUL2 BDH1

2.55e-03196922121_DN
Drugfelodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA

ZNF318 HNRNPUL2

2.55e-0319692848_DN
DrugY-27632; Down 200; 3uM; MCF7; HT_HG-U133A_EA

ZNF318 HNRNPUL2

2.55e-0319692832_DN
Drugfluphenazine dihydrochloride; Down 200; 10uM; HL60; HT_HG-U133A

CUL2 ZNF318

2.55e-03196921178_DN
DrugDoxycycline hydrochloride [10592-13-9]; Down 200; 8.4uM; HL60; HT_HG-U133A

CUL2 HNRNPUL2

2.55e-03196922737_DN
DrugKetoconazole [65277-42-1]; Down 200; 7.6uM; PC3; HT_HG-U133A

ZNF318 HNRNPUL2

2.55e-03196924624_DN
DrugHesperetin [520-33-2]; Down 200; 13.2uM; MCF7; HT_HG-U133A

HNRNPUL2 FBXO46

2.55e-03196921531_DN
Drug(+,-)-Synephrine [94-07-5]; Down 200; 24uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.55e-03196926798_DN
Drug2-propylpentanoic acid; Up 200; 200uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.55e-03196926934_UP
Drugrapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

CUL2 HNRNPUL2

2.55e-0319692921_DN
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.55e-03196925240_DN
DrugNorethynodrel [68-23-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.55e-03196921696_DN
DrugMefloquine hydrochloride [51773-92-3]; Down 200; 9.6uM; PC3; HT_HG-U133A

HNRNPUL2 BDH1

2.55e-03196925724_DN
DrugHydrochlorothiazide [58-93-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.55e-03196921487_DN
Drugfluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A

HNRNPUL2 BDH1

2.55e-03196926954_DN
Drug5152487; Down 200; 10uM; MCF7; HT_HG-U133A_EA

CUL2 HNRNPUL2

2.55e-0319692896_DN
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A

HNRNPUL2 FBXO46

2.55e-03196926813_DN
DrugOxybenzone [131-57-7]; Down 200; 17.6uM; PC3; HT_HG-U133A

ZNF318 FBXO46

2.55e-03196926309_DN
DrugDimethadione [695-53-4]; Down 200; 31uM; HL60; HT_HG-U133A

CUL2 FBXO46

2.55e-03196923029_DN
DrugLY 294002; Down 200; 0.1uM; PC3; HT_HG-U133A

FBXO46 BDH1

2.55e-03196921216_DN
DrugChelidonine monohydrate (+) [476-32-4]; Down 200; 10.8uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.55e-03196926236_DN
DrugMeprylcaine hydrochloride [956-03-6]; Down 200; 14.8uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.58e-03197923544_DN
DrugAlcuronium chloride [15180-03-7]; Down 200; 5.4uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.58e-03197927345_DN
DrugMethacycline hydrochloride [3963-95-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.58e-03197927321_DN
DrugTriamterene [396-01-0]; Up 200; 15.8uM; MCF7; HT_HG-U133A

ZNF318 MMP17

2.58e-03197926010_UP
DrugKetoconazole [65277-42-1]; Down 200; 7.6uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.58e-03197925685_DN
Drug1-phenylbiguanide hydrochloride; Up 200; 10uM; MCF7; HG-U133A

ZNF318 MMP17

2.58e-031979222_UP
DrugPraziquantel [55268-74-1]; Up 200; 12.8uM; PC3; HT_HG-U133A

ZNF318 LILRA4

2.58e-03197925874_UP
DrugFluoxetine hydrochloride [59333-67-4]; Down 200; 11.6uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.58e-03197925356_DN
DrugDiphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; HL60; HT_HG-U133A

CUL2 HNRNPUL2

2.58e-03197921871_UP
DrugPhensuximide [86-34-0]; Down 200; 21.2uM; PC3; HT_HG-U133A

FBXO46 BDH1

2.58e-03197925097_DN
DrugLevocabastine hydrochloride [79547-78-7]; Down 200; 8.8uM; PC3; HT_HG-U133A

ZNF318 FBXO46

2.58e-03197927249_DN
DrugFlavoxate hydrochloride [3717-88-2]; Down 200; 9.4uM; PC3; HT_HG-U133A

ZNF318 HNRNPUL2

2.58e-03197926326_DN
DrugIpratropium bromide [22254-24-6]; Up 200; 9.8uM; PC3; HT_HG-U133A

MMP17 HNRNPUL2

2.58e-03197925823_UP
DrugMemantine Hydrochloride [41100-52-1]; Down 200; 18.6uM; HL60; HT_HG-U133A

CUL2 HNRNPUL2

2.58e-03197922934_DN
DrugMetaproterenol sulfate, orciprenaline sulfate [5874-97-5]; Down 200; 7.6uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.58e-03197922845_DN
DrugPheniramine maleate [132-20-7]; Down 200; 11.2uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.58e-03197921492_DN
DrugMethylatropine nitrate [52-88-0]; Down 200; 11uM; PC3; HT_HG-U133A

ZNF318 FBXO46

2.58e-03197927253_DN
DrugSB 202190; Up 200; 1uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.60e-03198926909_UP
DrugMebendazole [31431-39-7]; Down 200; 13.6uM; PC3; HT_HG-U133A

ZNF318 BDH1

2.60e-03198927370_DN
DrugSuramin sodium salt; Up 200; 10uM; MCF7; HT_HG-U133A

MMP17 HNRNPUL2

2.60e-03198927524_UP
DrugAcacetin [480-44-4]; Up 200; 14uM; PC3; HT_HG-U133A

MMP17 HNRNPUL2

2.60e-03198923767_UP
DrugGramine [87-52-5]; Down 200; 23uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.60e-03198922799_DN
DrugDimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A

ZNF318 HNRNPUL2

2.60e-03198926520_UP
DrugSulfaphenazole [526-08-9]; Up 200; 12.8uM; MCF7; HT_HG-U133A

ZNF318 MMP17

2.60e-03198925507_UP
Drugestradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A

CUL2 FBXO46

2.60e-03198926957_UP
DrugZalcitabine [7481-89-2]; Down 200; 19uM; PC3; HT_HG-U133A

HNRNPUL2 FBXO46

2.60e-03198924215_DN
DrugMetformin hydrochloride [1115-70-4]; Down 200; 24.2uM; MCF7; HT_HG-U133A

CUL2 FBXO46

2.60e-03198921694_DN
DrugDimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; MCF7; HT_HG-U133A

ZNF318 FBXO46

2.60e-03198924791_DN
DrugEnalapril maleate [76095-16-4]; Down 200; 8.2uM; MCF7; HT_HG-U133A

ZNF318 FBXO46

2.60e-03198927428_DN
DrugFendiline hydrochloride [13636-18-5]; Down 200; 11.4uM; MCF7; HT_HG-U133A

CUL2 ZNF318

2.60e-03198923190_DN
Drughaloperidol; Down 200; 10uM; MCF7; HT_HG-U133A_EA

CUL2 HNRNPUL2

2.60e-0319892983_DN
DrugPHA-00767505E [723337-45-9]; Up 200; 10uM; MCF7; HT_HG-U133A

ZNF318 FBXO46

2.60e-03198926550_UP
DrugBendroflumethiazide [73-48-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A

CUL2 HNRNPUL2

2.60e-03198923415_UP
Diseaseeosinophil count

CUL2 MMP17 FBXO46 SEC16A

3.83e-04148884EFO_0004842
DiseaseCalcium channel blocker use measurement

ZNF318 RNF213

1.41e-0321382EFO_0009930
Diseasevisual perception measurement

LILRA4 BDH1

1.55e-0322382EFO_0009700
Diseasehypertension

ZNF318 RNF213

2.90e-0330782EFO_0000537
Diseasemigraine disorder

MMP17 RNF213

3.89e-0335782MONDO_0005277
Diseasemean arterial pressure

ZNF318 RNF213

7.47e-0349982EFO_0006340

Protein segments in the cluster

PeptideGeneStartEntry
PYTRYHPMDYYWWLR

BDH1

311

Q02338
PSMMWEHAGRYHCYY

LILRA4

86

P59901
PYHHDLPYGRSYWMC

FBXO46

551

Q6PJ61
DWQSYYYHHPQDRDR

HNRNPUL2

721

Q1KMD3
MYHRYWEEYSKGADY

CUL2

86

Q13617
YWRYDDHTRHMDPGY

MMP17

451

Q9ULZ9
DWHQYYDIVYMKPHG

RNF213

491

Q63HN8
ENHRYMYWYRQDPGH

TRBV10-3

46

A0A0K0K1G6
YGDPGHWDRYHYSAR

SEC16A

1266

O15027
YRHYMAYAASRWPMY

ZNF318

791

Q5VUA4